South Africa: Vaccine Trial Leaders Dismiss Top Adviser's Claims They Could Have Secured SA Access

(file image).

Researchers could have secured access to Covid-19 vaccine supplies when they agreed to conduct local clinical trials, SA's top vaccine adviser Professor Barry Schoub has argued. Trial leaders have dismissed the claims and called on stakeholders to stop shifting blame and develop realistic vaccination plans.

The chairperson of the ministerial advisory committee (MAC) on Covid-19 vaccines, Professor Barry Schoub, has claimed researchers missed the opportunity to leverage the country's participation in clinical trials to secure access to vaccines once they became available.

Schoub made the comments during an interview with Judge Dennis Davis, published on Wednesday, while the state faces criticism for failing to conclude any bilateral agreements with vaccine manufacturers.

He said the country's ability to access vaccines went wrong when leaders of clinical trials did not insist that manufacturers are contractually obliged to supply their products to South Africa.

"It should have been a commitment as part of their arrangement. We didn't do that. We could have had Johnson & Johnson. We could have had AstraZeneca and to some extent also Pfizer because they were trialled here," said Schoub.

Clinical trials were conducted in South Africa for the Oxford-AstraZeneca, Johnson & Johnson, Pfizer-BioNTech and Novavax vaccines. The efficacy...

More From: Daily Maverick

Don't Miss

AllAfrica publishes around 800 reports a day from more than 130 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.